(Q44446461)

3 December 2017

title

Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid (English)

1 reference

Michel Jean Robert Perricaudet

3 December 2017

1 reference

series ordinal

3

object named as

Michel Perricaudet

1 reference

3 December 2017

4

Karim Benihoud

1 reference

3 December 2017

Anastasia Lanzi

1

1 reference

3 December 2017

Ghada Ben Youssef

series ordinal

2

1 reference

3 December 2017

language of work or name

English

0 references

publication date

22 December 2010

1 reference

3 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

3 December 2017

volume

29

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

1463-1471

1 reference

Adenoviruses as vaccine vectors

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Replication-defective vector based on a chimpanzee adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Chimpanzee-origin adenovirus vectors as vaccine carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Genetic targeting of adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Characterization of a permissive epitope insertion site in adenovirus hexon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Recombinational construction in Escherichia coli of infectious adenoviral genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Specific antibodies modulate the interactions of adenovirus type 5 with dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.12.025

1 reference

3 December 2017

1 reference